Caxton Associates LP acquired a new position in shares of Veru Inc. (NASDAQ:VERU) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 33,441 shares of the company’s stock, valued at approximately $360,000.
Other hedge funds also recently added to or reduced their stakes in the company. RMR Wealth Builders raised its holdings in Veru by 877.6% during the first quarter. RMR Wealth Builders now owns 2,395 shares of the company’s stock worth $26,000 after purchasing an additional 2,150 shares in the last quarter. Signaturefd LLC acquired a new stake in Veru during the first quarter worth approximately $27,000. Altshuler Shaham Ltd acquired a new stake in Veru during the first quarter worth approximately $34,000. O Shaughnessy Asset Management LLC increased its holdings in shares of Veru by 1,877.1% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 3,974 shares of the company’s stock valued at $43,000 after acquiring an additional 3,773 shares during the period. Finally, Captrust Financial Advisors acquired a new position in shares of Veru in the 1st quarter valued at $43,000. 33.47% of the stock is currently owned by institutional investors.
A number of equities analysts have recently commented on VERU shares. Zacks Investment Research raised shares of Veru from a “sell” rating to a “hold” rating in a report on Tuesday, May 25th. TheStreet cut shares of Veru from a “c” rating to a “d+” rating in a report on Wednesday, May 12th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Veru in a report on Monday, June 28th. Finally, Jefferies Financial Group started coverage on shares of Veru in a report on Tuesday, April 13th. They issued a “buy” rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Veru presently has an average rating of “Buy” and a consensus price target of $17.13.
NASDAQ:VERU opened at $7.41 on Thursday. The firm has a fifty day moving average price of $8.18. Veru Inc. has a 1-year low of $2.30 and a 1-year high of $24.57.
Veru (NASDAQ:VERU) last posted its quarterly earnings data on Wednesday, May 12th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Veru had a negative net margin of 0.95% and a negative return on equity of 11.24%. The firm had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $14.36 million. As a group, equities analysts anticipate that Veru Inc. will post -0.21 earnings per share for the current year.
Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.
Featured Article: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.